$CTGO
Contango ORE, Inc.

2017 Q4 Form 10-Q Financial Statement

#000143774918001352 Filed on January 31, 2018

View on sec.gov

Income Statement

Concept 2017 Q4 2016 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $810.0K $590.0K
YoY Change 37.29% 84.38%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $810.0K $590.0K
YoY Change 37.29% 84.38%
Operating Profit
YoY Change
Interest Expense $0.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$810.0K -$590.0K
YoY Change 37.29% 84.38%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$808.3K -$592.1K
YoY Change 36.51% 86.12%
Net Earnings / Revenue
Basic Earnings Per Share -$0.14 -$0.13
Diluted Earnings Per Share -$0.14 -$0.13
COMMON SHARES
Basic Shares Outstanding 5.650M 4.640M
Diluted Shares Outstanding 5.650M 4.640M

Balance Sheet

Concept 2017 Q4 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $15.82M $5.790M
YoY Change 173.23% 299.31%
Cash & Equivalents $15.82M $5.792M
Short-Term Investments
Other Short-Term Assets $130.0K $120.0K
YoY Change 8.33% 9.09%
Inventory
Prepaid Expenses $125.6K $120.1K
Receivables
Other Receivables
Total Short-Term Assets $15.95M $5.913M
YoY Change 169.72% 279.23%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $15.95M $5.913M
Total Long-Term Assets $0.00 $0.00
Total Assets $15.95M $5.913M
YoY Change 169.72% 279.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.12K $40.14K
YoY Change -67.32% 24.97%
Accrued Expenses $117.8K $145.3K
YoY Change -18.91% 757.06%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $130.9K $185.4K
YoY Change -29.39% 277.87%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $130.9K $185.4K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $130.0K $190.0K
YoY Change -31.58% 280.0%
SHAREHOLDERS EQUITY
Retained Earnings -$36.59M -$33.82M
YoY Change 8.18% 6.28%
Common Stock $52.41M $39.72M
YoY Change 31.93% 19.16%
Preferred Stock
YoY Change
Treasury Stock (at cost) $171.2K
YoY Change
Treasury Stock Shares $0.00 $7.185K
Shareholders Equity $15.82M $5.727M
YoY Change
Total Liabilities & Shareholders Equity $15.95M $5.913M
YoY Change 169.72% 279.23%

Cashflow Statement

Concept 2017 Q4 2016 Q4
OPERATING ACTIVITIES
Net Income -$808.3K -$592.1K
YoY Change 36.51% 86.12%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$190.0K -$470.0K
YoY Change -59.57% 38.24%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 11.07M 5.120M
YoY Change 116.21%
NET CHANGE
Cash From Operating Activities -190.0K -470.0K
Cash From Investing Activities
Cash From Financing Activities 11.07M 5.120M
Net Change In Cash 10.88M 4.650M
YoY Change 133.98% -1467.65%
FREE CASH FLOW
Cash From Operating Activities -$190.0K -$470.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
117808
CY2017Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
86561
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
52345624
CY2017Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
40500239
CY2017Q4 ctgo Number Of Wholly Owned Subsidiaries
NumberOfWhollyOwnedSubsidiaries
2
CY2017Q4 ctgo Options And Warrants Outstanding
OptionsAndWarrantsOutstanding
271000
CY2017Q2 ctgo Options And Warrants Outstanding
OptionsAndWarrantsOutstanding
845999
ctgo Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1187491
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13116
CY2017Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
50858
CY2017Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2016Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4537964
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
998117
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
642143
CY2017Q4 us-gaap Assets
Assets
15947298
CY2017Q2 us-gaap Assets
Assets
5367540
CY2017Q4 us-gaap Assets Current
AssetsCurrent
15947298
CY2017Q2 us-gaap Assets Current
AssetsCurrent
5367540
us-gaap Basis Of Accounting
BasisOfAccounting
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.</div> Basis of Presentation</div></div> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 24pt; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;The accompanying unaudited consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for interim financial information, pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;), including instructions to Form <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-Q and Article <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div> of Regulation S-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">X.</div> Accordingly, they do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include all the information and footnotes required by GAAP for complete annual consolidated financial statements. In the opinion of management, all adjustments considered necessary for a fair statement of the consolidated financial statements have been included. All such adjustments are of a normal recurring nature. The consolidated financial statements should be read in conjunction with the audited financial statements and notes included in the Company<div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#x2019;s Form <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-K for the fiscal year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> The results of operations for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017&nbsp;</div>are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> necessarily indicative of the results that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be expected for the fiscal year ending <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018.</div></div></div></div>
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15821738
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5191749
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1254489
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5792453
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
10629989
CY2017Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
271000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5975048
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4930231
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5975048
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4921163
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
59751
CY2017Q2 us-gaap Common Stock Value
CommonStockValue
49303
CY2017Q4 us-gaap Costs And Expenses
CostsAndExpenses
808344
CY2016Q4 us-gaap Costs And Expenses
CostsAndExpenses
592142
us-gaap Costs And Expenses
CostsAndExpenses
1476980
us-gaap Costs And Expenses
CostsAndExpenses
1547792
CY2017Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2016Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2017Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
130924
CY2017Q2 us-gaap Liabilities Current
LiabilitiesCurrent
137419
CY2017Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2017Q2 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
CY2017Q4 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2017Q4 us-gaap Equity Method Investments
EquityMethodInvestments
CY2017Q2 us-gaap Equity Method Investments
EquityMethodInvestments
CY2017Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
808344
CY2016Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
592142
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1476980
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1547792
CY2017Q4 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
CY2016Q4 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-6495
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
71681
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-50231
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
61917
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15947298
CY2017Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5367540
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11065116
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5116342
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-435127
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-578378
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-808344
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-592142
us-gaap Net Income Loss
NetIncomeLoss
-1476980
us-gaap Net Income Loss
NetIncomeLoss
-1547792
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4315444
CY2017Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5650321
CY2016Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4640034
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5289934
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
171158
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
125560
CY2017Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
175791
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
11065116
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
5287500
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-36589001
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-35112021
CY2010Q4 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
1600000
us-gaap Share Based Compensation
ShareBasedCompensation
998117
us-gaap Share Based Compensation
ShareBasedCompensation
959650
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10519768
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
15816374
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
5230121
us-gaap Treasury Stock Retired Cost Method Amount
TreasuryStockRetiredCostMethodAmount
CY2017Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
0
CY2017Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
9068
CY2017Q4 us-gaap Treasury Stock Value
TreasuryStockValue
CY2017Q2 us-gaap Treasury Stock Value
TreasuryStockValue
207400
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 27pt;"><div style="display: inline; font-style: italic;">Management Estimates.</div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">&nbsp;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates</div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">.</div></div></div></div></div>
CY2017Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5650321
CY2016Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4640034
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5289934
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4315444
CY2017Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5650321
CY2016Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4640034
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5289934
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4315444

Files In Submission

Name View Source Status
0001437749-18-001352-index-headers.html Edgar Link pending
0001437749-18-001352-index.html Edgar Link pending
0001437749-18-001352.txt Edgar Link pending
0001437749-18-001352-xbrl.zip Edgar Link pending
a2016phase1explorationprogra.jpg Edgar Link pending
conta20171231_10q.htm Edgar Link pending
ctgo-20171231.xml Edgar Link completed
ctgo-20171231.xsd Edgar Link pending
ctgo-20171231_cal.xml Edgar Link unprocessable
ctgo-20171231_def.xml Edgar Link unprocessable
ctgo-20171231_lab.xml Edgar Link unprocessable
ctgo-20171231_pre.xml Edgar Link unprocessable
ex_102844.htm Edgar Link pending
ex_102845.htm Edgar Link pending
ex_102846.htm Edgar Link pending
ex_102847.htm Edgar Link pending
ex_103949.htm Edgar Link pending
ex_103949.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gradexthicknessmainpeakandno.jpg Edgar Link pending
phase3map.jpg Edgar Link pending
phaseiiimap.jpg Edgar Link pending
phaseiimapwallholes.jpg Edgar Link pending
phaseimap.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tetlinmapphaseii2016program.jpg Edgar Link pending